Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000296316 | SCV000333246 | uncertain significance | not provided | 2018-05-10 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000673100 | SCV000798268 | uncertain significance | Lysosomal acid lipase deficiency | 2018-03-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001391322 | SCV001080072 | likely benign | Wolman disease | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002446516 | SCV002680615 | likely benign | Cardiovascular phenotype | 2023-07-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV000673100 | SCV002091333 | likely benign | Lysosomal acid lipase deficiency | 2020-03-30 | no assertion criteria provided | clinical testing |